Opportunity Information: Apply for PAR 13 252
Apply for PAR 13 252
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.351 Research Infrastructure Programs 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jul 3, 2013 and posted on Jul 3, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Independent school districts City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Special district governments For profit organizations other than small businesses Private institutions of higher education Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-13-252, titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)," is a discretionary grant program that supports Resource-Related Research Project Grant (R24) applications focused on strengthening the scientific foundation needed to move stem cell-based regenerative medicine closer to reliable clinical use. At its core, the opportunity is designed to help the research community develop better animal-based resources for evaluating stem cell therapies by improving how animal stem cells are understood, how stem cells are characterized and transplanted, and how well animal disease models reflect human conditions. The overall intent is practical and translational: to make preclinical studies more predictive so that stem cell-based approaches can be tested more rigorously and efficiently before they reach human trials.
The announcement emphasizes that many stem cell therapies fail to translate smoothly from early studies to human application partly because the available animal models and stem cell characterization methods are not always comparable to human biology in the ways that matter most for treatment. In response, the FOA encourages projects that directly address gaps in model relevance, biological comparability, and technical capability. Rather than funding a narrow hypothesis-driven project, the R24 mechanism typically supports resource-building efforts that can benefit an entire research field, such as shared model systems, standardized characterization methods, broadly usable datasets, enabling tools, or improved protocols that other investigators can adopt.
The initiative highlights three main scientific priorities. First is comparative analysis of animal and human stem cells. This area aims to generate clear, evidence-based information about how stem cells from different animal species align with human stem cells in terms of developmental potential, molecular signatures, functional behavior, immunologic properties, and response to injury or disease signals. The practical outcome NIH is steering toward is better guidance on which animal model is most predictive for a given regenerative medicine question, since different tissues and diseases may require different model systems. Second is development of new technologies for stem cell characterization and transplantation. This includes improved ways to identify, measure, track, and assess stem cell populations and their derivatives, as well as better transplantation techniques, monitoring tools, imaging approaches, and methods to evaluate engraftment, survival, differentiation, integration, and safety outcomes such as aberrant growth. Third is improvement of animal disease models specifically for stem cell-based therapeutic applications, meaning models that more faithfully reproduce human disease features that are critical for judging whether a stem cell therapy is likely to work, how durable the effect might be, and what risks or complications could occur.
Administratively, this opportunity was issued by the National Institutes of Health and uses the grant funding instrument. It is tied to health-related funding activity and is associated with CFDA numbers 93.351 (Research Infrastructure Programs), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research, as listed in the source). The FOA was posted and created on July 3, 2013, with an original and current closing date of September 7, 2016, and an archive date of October 8, 2016. The listing indicates there is no cost sharing or matching requirement, which generally means applicants are not expected to provide mandatory matching funds as a condition of the award.
Eligibility is broad across U.S.-based organizations and government entities, reflecting NIH interest in enabling wide participation from academic, nonprofit, and certain for-profit sectors involved in biomedical model development. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status (with the noted exception category), small businesses, and for-profit organizations other than small businesses, as well as state, county, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly includes a range of mission-focused and community-linked institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations and certain regional organizations. At the same time, the opportunity makes clear that non-U.S. entities are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed, which keeps the funding focused on domestic infrastructure and resource development.
From a practical standpoint, a competitive application under this FOA would be expected to propose work that clearly improves the reliability, usefulness, and accessibility of animal model systems for regenerative medicine using stem cells. That could mean demonstrating that a proposed model better predicts human outcomes, establishing robust cross-species benchmarks for stem cell identity and function, or delivering tools and protocols that reduce variability and increase reproducibility across laboratories. Because the mechanism is resource-related, reviewers typically look for projects with field-wide impact, strong plans for dissemination or sharing, and approaches that can become part of the broader research toolkit for evaluating stem cell-based therapies in relevant disease contexts.
The full announcement was made available through the NIH grants website at http://grants.nih.gov/grants/guide/pa-files/PAR-13-252.html. For technical access issues with the electronic posting or linking problems, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs) - NIH PAR-13-252 (R24)
What is the funding opportunity PAR-13-252?
PAR-13-252 is an NIH funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)." It supports Resource-Related Research Project Grant (R24) applications aimed at improving animal-based resources and methods used to evaluate stem cell-based regenerative medicine approaches before they move into human clinical trials.
What is the main goal of this NIH program?
The program is intended to strengthen the scientific foundation needed to make stem cell-based regenerative medicine more reliable and clinically translatable. The focus is on improving how animal models and animal stem cell resources are developed and used so that preclinical findings are more predictive of human outcomes.
What type of grant mechanism is used?
This opportunity uses the NIH R24 mechanism, described as a Resource-Related Research Project Grant. It typically supports resource-building efforts that can benefit a broad research community rather than a narrow, single-hypothesis project.
What kinds of projects does an R24 resource-related program typically support under this FOA?
Based on the description provided, projects are expected to build or improve resources that many investigators can use, such as shared animal model systems, standardized stem cell characterization methods, broadly usable datasets, enabling tools, or improved protocols for transplantation and evaluation in animal disease models.
Why is NIH emphasizing improved animal models for stem cell therapies?
The announcement notes that many stem cell therapies do not translate smoothly from early studies to human application, partly because existing animal models and characterization methods may not align with human biology in the ways that matter most for treatment decisions. NIH is encouraging work that closes gaps in relevance, comparability, and technical capability so preclinical testing is more rigorous and efficient.
What are the main scientific priority areas in this opportunity?
The FOA highlights three priorities: (1) comparative analysis of animal and human stem cells; (2) development of new technologies for stem cell characterization and transplantation; and (3) improvement of animal disease models for stem cell-based therapeutic applications.
What does "comparative analysis of animal and human stem cells" mean in this context?
This priority focuses on generating evidence-based information about how stem cells from different animal species align with human stem cells. The comparison areas mentioned include developmental potential, molecular signatures, functional behavior, immunologic properties, and responses to injury or disease signals. The practical aim is to guide which animal model is most predictive for specific regenerative medicine questions.
What types of technology development are encouraged for stem cell characterization and transplantation?
The FOA encourages improved ways to identify, measure, track, and assess stem cell populations and their derivatives, along with better transplantation techniques and monitoring tools. The description specifically mentions imaging approaches and methods to evaluate engraftment, survival, differentiation, integration, and safety outcomes such as aberrant growth.
What does "improvement of animal disease models" mean for stem cell-based therapeutics?
It means creating or refining animal disease models so they more faithfully reproduce human disease features that are critical for judging whether a stem cell therapy is likely to work, how durable the effect may be, and what risks or complications could occur.
Is this opportunity intended to be basic science, translational, or clinical?
The stated intent is practical and translational: improving preclinical resources and models so that stem cell-based approaches can be tested more rigorously and efficiently before entering human trials.
Who is the issuing agency for this opportunity?
The opportunity was issued by the National Institutes of Health (NIH).
What is the funding instrument used?
The listing states this is a grant funding instrument.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.351 (Research Infrastructure Programs), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research), as listed in the source description.
When was PAR-13-252 posted and created?
The FOA was posted and created on July 3, 2013.
What were the closing date and archive date for this opportunity?
The original and current closing date listed is September 7, 2016, and the archive date is October 8, 2016.
Is cost sharing or matching required?
No. The listing indicates there is no cost sharing or matching requirement.
Which organizations are eligible to apply?
Eligibility is broad across U.S.-based organizations and government entities. Eligible applicants listed include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status (with the noted exception category), small businesses, and for-profit organizations other than small businesses. Eligible government entities include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are minority-serving and community-linked institutions included as eligible applicants?
Yes. The FOA explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and certain regional organizations.
Are foreign (non-U.S.) organizations eligible to apply?
No. The opportunity states that non-U.S. entities are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. The FOA specifies that non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this FOA?
No. The opportunity indicates that foreign components (as defined by NIH policy) are not allowed.
What would NIH likely consider a strong application under this FOA (based on the description provided)?
The description suggests that competitive applications would propose work that clearly improves the reliability, usefulness, and accessibility of animal model systems for stem cell-based regenerative medicine. Examples of the kinds of outcomes emphasized include better prediction of human outcomes, robust cross-species benchmarks for stem cell identity and function, and tools or protocols that reduce variability and increase reproducibility across laboratories.
Does the FOA emphasize sharing or dissemination of developed resources?
Yes. Because this is a resource-related mechanism, the description notes that reviewers typically look for field-wide impact and strong plans for dissemination or sharing, so that outputs can become part of the broader research toolkit.
Where can applicants find the full FOA text?
The full announcement is available on the NIH grants website at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-252.html.
Who should be contacted for technical issues with the electronic posting or linking problems?
For technical access issues with the electronic posting or linking problems, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Providing Support for the Collaborative Improvement and Innovation Network (CoIIN) to Reduce Infant M
Previous opportunity: Women in Development for Prosperity Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 252
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 252) also looked into and applied for these:
| Funding Opportunity |
|---|
| Providing Support for the Collaborative Improvement and Innovation Network (CoIIN) to Reduce Infant M Apply for HRSA 13 282 Funding Number: HRSA 13 282 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,000,000 |
| Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis Apply for SOL OAA 13 000107 Funding Number: SOL OAA 13 000107 Agency: Agency for International Development Category: Health Funding Amount: $35,000,000 |
| Secondary Analyses of Alcohol and Chronic Disease (R21) Apply for PA 13 251 Funding Number: PA 13 251 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analyses of Alcohol and Chronic Disease (R01) Apply for PA 13 260 Funding Number: PA 13 260 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Alcohol and Chronic Disease (R03) Apply for PA 13 261 Funding Number: PA 13 261 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Dose Response and Efficacy Studies on the Effects of Vitamin D Supplementation on Functional Outcomes in Elderly (U01) Apply for RFA AG 14 001 Funding Number: RFA AG 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implications of New Digital Media Use for Underage Drinking, Drinking Related Behaviors, and Prevention Research (R21) Apply for PA 13 263 Funding Number: PA 13 263 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Implications of New Digital Media Use for Underage Drinking, Drinking Related Behaviors, and Prevention Research (R01) Apply for PA 13 262 Funding Number: PA 13 262 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel NeuroAIDS Therapeutics Integrated Preclinical/Clinical Program (P01) Apply for PAR 13 267 Funding Number: PAR 13 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Developing a Point of Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings SBIR (R43/ R44) Apply for RFA HL 14 010 Funding Number: RFA HL 14 010 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| NEI Center Core Grants for Vision Research (P30) Apply for PAR 13 269 Funding Number: PAR 13 269 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health Promotion and Disease Prevention Research Centers Apply for RFA DP 14 001 Funding Number: RFA DP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Urban Indian Education and Research Organization Cooperative Agreement Program Apply for HHS 2013 IHS OUIHP 0001 Funding Number: HHS 2013 IHS OUIHP 0001 Agency: Indian Health Service Category: Health Funding Amount: $800,000 |
| NINDS Clinical Trial Methods in Clinical Neurological Disorders Course (R25) Apply for RFA NS 14 001 Funding Number: RFA NS 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Researcher Training and Workforce Development in Methods and Standards for Conducting Patient Centered Outcomes Research Studies (R25) Apply for RFA HS 14 004 Funding Number: RFA HS 14 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA GM 14 014 Funding Number: RFA GM 14 014 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Mentored Research Scientist Development Award (K01) Apply for PAR 13 245 Funding Number: PAR 13 245 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Formula Grant Program Apply for HRSA 13 278 Funding Number: HRSA 13 278 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood Pressure Measurement Technologies for Low Resource Settings in the U.S. and India (U01) Apply for RFA EB 13 001 Funding Number: RFA EB 13 001 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Emerging Priorities in Reproductive, Maternal and Newborn Health Apply for APS OAA 13 000005 Funding Number: APS OAA 13 000005 Agency: Agency for International Development Category: Health Funding Amount: $9,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 252", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.